Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a open-label single-arm study of cannabidiol as a steroid-sparing maintenance therapy in stable autoimmune hepatitis
MOH_2019-02-11_004895Phase 2Not yet recruiting
- Sponsor
- STERO Biotechs
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cannabidiol in autoimmune hepatitis (AIH), sponsored by STERO Biotechs. Primary endpoints: Safety of cannabidiol as maintenance therapy, Tolerability of cannabidiol as maintenance therapy and 1 more. Planned start Dec 2018; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
autoimmune hepatitis (AIH)
Beyond the preview
Go deeper on MOH_2019-02-11_004895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-11_004895.